Comparison of change in lipoprotein(a) mass and molar concentrations by alirocumab and risk of subsequent cardiovascular events in ODYSSEY OUTCOMES.
Saved in:
| Title: | Comparison of change in lipoprotein(a) mass and molar concentrations by alirocumab and risk of subsequent cardiovascular events in ODYSSEY OUTCOMES. |
|---|---|
| Authors: | Szarek M; Division of Cardiology, University of Colorado School of Medicine, Box B130, Aurora, CO 80045, USA.; CPC Clinical Research, 2115 N. Scranton Street, Suite 2040, Aurora, CO 80045, USA.; Department of Epidemiology and Biostatistics, State University of New York, Downstate Health Sciences University School of Public Health, 450 Clarkson Avenue, Brooklyn, NY 11203, USA., Reijnders E; Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Centre, LUMC Main Building, Albinusdreef 2, 2333 ZA Leiden, The Netherlands., Steg PG; Université Paris-Cité, 85 boulevard Saint-Germain, 75006 Paris, France.; Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, FACT (French Alliance for Cardiovascular Trials), INSERM U1148, 46 rue Henri Huchard, 75018 Paris, France.; Institut Universitaire de France, 1 rue Descartes, 75005 Paris, France., Jukema JW; Department of Cardiology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands.; Netherlands Heart Institute, Moreelsepark 1, 3511 EP Utrecht, The Netherlands., Schwertfeger M; RCardiometabolism, Neuroscience, Endocrinology, PHCS, PoC, RDS Clinical Development and Medical Affairs (CDMA), Roche Diagnostics International Ltd., Building 5/Floor 10, Forrenstrasse 2, 6343 Rotkreuz, Switzerland., Bhatt DL; Mount Sinai Heart, Icahn School of Medicine at Mount Sinai Health System, 1 Gustave Levy Place, Box 1030, New York, NY 10029, USA., Bittner VA; Division of Cardiovascular Disease, University of Alabama at Birmingham, 701 19th Street South - LHRB 310, Birmingham, AL 35294, USA., Diaz R; Estudios Cardiológicos Latino América, Instituto Cardiovascular de Rosario, Paraguay 160, Rosario, Santa Fe, Rosario 2000, Argentina., Fazio S; Scientific Council -Cardiometabolic Global Development, Regeneron Pharmaceuticals Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA., Garon G; Global Medical Department - General Medicines GBU, Sanofi, Ontario M2R 3T4, Canada., Goodman SG; Canadian VIGOUR Centre, University of Alberta, 87 Ave NW, Edmonton, Alberta T6G 2E1, Canada.; Division of Cardiology, St. Michael's Hospital, Room 6-034 Donnelly Wing, Toronto, Ontario M5B 1W8, Canada., Harrington RA; Stephen and Suzanne Weiss Dean, Weill Cornell Medicine, 1300 York Avenue, F-113, New York, NY 10065, USA., White HD; Green Lane Cardiovascular Services, Auckland City Hospital, 5 Park Road, Grafton, Auckland 1142, New Zealand., Zeiher AM; Department of Medicine III, Goethe University, Theodor-Stern-Kai 7, Frankfurt am Main 60590, Germany., Cobbaert C; Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Centre, LUMC Main Building, Albinusdreef 2, 2333 ZA Leiden, The Netherlands., Schwartz GG; Division of Cardiology, University of Colorado School of Medicine, Box B130, Aurora, CO 80045, USA. |
| Source: | European journal of preventive cardiology [Eur J Prev Cardiol] 2024 Aug 09; Vol. 31 (10), pp. e75-e78. |
| Publication Type: | Comparative Study; Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 101564430 Publication Model: Print Cited Medium: Internet ISSN: 2047-4881 (Electronic) Linking ISSN: 20474873 NLM ISO Abbreviation: Eur J Prev Cardiol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
